Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

Michael A. Thompson; Mario Boccadoro; Xavier Leleu; Jorge Vela-Ojeda; Frits van Rhee; Katja C. Weisel; Robert M. Rifkin; Saad Z. Usmani; Roman Hájek; Gordon Cook; Rafat Abonour; Mira Armour; Kathryn E. Morgan; Su Peng Yeh; Caitlin L. Costello; Jesus G. Berdeja; Faith E. Davies; Jeffrey A. Zonder; Hans C. Lee; Jim Omel; Andrew Spencer; Evangelos Terpos; Vania T.M. Hungria; Noemi Puig; Chengcheng Fu; Renda H. Ferrari; Kaili Ren; Dawn Marie Stull; Ajai Chari

doi:10.1016/j.clml.2022.12.003

Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

Michael A. Thompson, Mario Boccadoro, Xavier Leleu, Jorge Vela-Ojeda, Frits van Rhee, Katja C. Weisel, Robert M. Rifkin, Saad Z. Usmani, Roman Hájek, Gordon Cook, Rafat Abonour, Mira Armour, Kathryn E. Morgan, Su Peng Yeh, Caitlin L. Costello, Jesus G. Berdeja, Faith E. Davies, Jeffrey A. Zonder, Hans C. Lee, Jim OmelAndrew Spencer, Evangelos Terpos, Vania T.M. Hungria, Noemi Puig, Chengcheng Fu, Renda H. Ferrari, Kaili Ren, Dawn Marie Stull, Ajai Chari

Lymphoma-Myeloma

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Infections are a common reason for hospitalization and death in multiple myeloma (MM). Although pneumococcal vaccination (PV) and influenza vaccination (FV) are recommended for MM patients, data on vaccination status and outcomes are limited in MM. Materials and Methods: We utilized data from the global, prospective, observational INSIGHT MM study to analyze FV and PV rates and associated outcomes of patients with MM enrolled 2016-2019. Results: Of the 4307 patients enrolled, 2543 and 2500 had study-entry data on FV and PV status. Overall vaccination rates were low (FV 39.6%, PV 30.2%) and varied by region. On separate multivariable analyses of overall survival (OS) by Cox model, FV in the prior 2 years and PV in the prior 5 years impacted OS (vs. no vaccination; FV: HR, 0.73; 95% CI, 0.60-0.90; P = .003; PV: HR, 0.51; 95% CI, 0.42-0.63; P < .0001) when adjusted for age, region, performance status, disease stage, cytogenetics at diagnosis, MM symptoms, disease status, time since diagnosis, and prior transplant. Proportions of deaths due to infections were lower among vaccinated versus non-vaccinated patients (FV: 9.8% vs. 15.3%, P = .142; PV: 9.9% vs. 18.0%, P = .032). Patients with FV had generally lower health resource utilization (HRU) versus patients without FV; patients with PV had higher or similar HRU versus patients without PV. Conclusion: Vaccination is important in MM and should be encouraged. Vaccination status should be recorded in prospective clinical trials as it may affect survival. This trial was registered at www.clinicaltrials.gov as #NCT02761187.

Original language	English (US)
Pages (from-to)	e171-e181
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	23
Issue number	3
DOIs	https://doi.org/10.1016/j.clml.2022.12.003
State	Published - Mar 2023

Keywords

Infection
Multiple myeloma
Supportive care
Survival
Vaccination

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2022.12.003

Cite this

Thompson, M. A., Boccadoro, M., Leleu, X., Vela-Ojeda, J., van Rhee, F., Weisel, K. C., Rifkin, R. M., Usmani, S. Z., Hájek, R., Cook, G., Abonour, R., Armour, M., Morgan, K. E., Yeh, S. P., Costello, C. L., Berdeja, J. G., Davies, F. E., Zonder, J. A., Lee, H. C., ... Chari, A. (2023). Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 23(3), e171-e181. https://doi.org/10.1016/j.clml.2022.12.003

Thompson, MA, Boccadoro, M, Leleu, X, Vela-Ojeda, J, van Rhee, F, Weisel, KC, Rifkin, RM, Usmani, SZ, Hájek, R, Cook, G, Abonour, R, Armour, M, Morgan, KE, Yeh, SP, Costello, CL, Berdeja, JG, Davies, FE, Zonder, JA, Lee, HC, Omel, J, Spencer, A, Terpos, E, Hungria, VTM, Puig, N, Fu, C, Ferrari, RH, Ren, K, Stull, DM & Chari, A 2023, 'Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients', Clinical Lymphoma, Myeloma and Leukemia, vol. 23, no. 3, pp. e171-e181. https://doi.org/10.1016/j.clml.2022.12.003

@article{97c7d3be300a495f969f137521eb5e25,

title = "Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients",

abstract = "Background: Infections are a common reason for hospitalization and death in multiple myeloma (MM). Although pneumococcal vaccination (PV) and influenza vaccination (FV) are recommended for MM patients, data on vaccination status and outcomes are limited in MM. Materials and Methods: We utilized data from the global, prospective, observational INSIGHT MM study to analyze FV and PV rates and associated outcomes of patients with MM enrolled 2016-2019. Results: Of the 4307 patients enrolled, 2543 and 2500 had study-entry data on FV and PV status. Overall vaccination rates were low (FV 39.6%, PV 30.2%) and varied by region. On separate multivariable analyses of overall survival (OS) by Cox model, FV in the prior 2 years and PV in the prior 5 years impacted OS (vs. no vaccination; FV: HR, 0.73; 95% CI, 0.60-0.90; P = .003; PV: HR, 0.51; 95% CI, 0.42-0.63; P < .0001) when adjusted for age, region, performance status, disease stage, cytogenetics at diagnosis, MM symptoms, disease status, time since diagnosis, and prior transplant. Proportions of deaths due to infections were lower among vaccinated versus non-vaccinated patients (FV: 9.8% vs. 15.3%, P = .142; PV: 9.9% vs. 18.0%, P = .032). Patients with FV had generally lower health resource utilization (HRU) versus patients without FV; patients with PV had higher or similar HRU versus patients without PV. Conclusion: Vaccination is important in MM and should be encouraged. Vaccination status should be recorded in prospective clinical trials as it may affect survival. This trial was registered at www.clinicaltrials.gov as #NCT02761187.",

keywords = "Infection, Multiple myeloma, Supportive care, Survival, Vaccination",

author = "Thompson, {Michael A.} and Mario Boccadoro and Xavier Leleu and Jorge Vela-Ojeda and {van Rhee}, Frits and Weisel, {Katja C.} and Rifkin, {Robert M.} and Usmani, {Saad Z.} and Roman H{\'a}jek and Gordon Cook and Rafat Abonour and Mira Armour and Morgan, {Kathryn E.} and Yeh, {Su Peng} and Costello, {Caitlin L.} and Berdeja, {Jesus G.} and Davies, {Faith E.} and Zonder, {Jeffrey A.} and Lee, {Hans C.} and Jim Omel and Andrew Spencer and Evangelos Terpos and Hungria, {Vania T.M.} and Noemi Puig and Chengcheng Fu and Ferrari, {Renda H.} and Kaili Ren and Stull, {Dawn Marie} and Ajai Chari",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = mar,

doi = "10.1016/j.clml.2022.12.003",

language = "English (US)",

volume = "23",

pages = "e171--e181",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "3",

}

TY - JOUR

T1 - Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

AU - Thompson, Michael A.

AU - Boccadoro, Mario

AU - Leleu, Xavier

AU - Vela-Ojeda, Jorge

AU - van Rhee, Frits

AU - Weisel, Katja C.

AU - Rifkin, Robert M.

AU - Usmani, Saad Z.

AU - Hájek, Roman

AU - Cook, Gordon

AU - Abonour, Rafat

AU - Armour, Mira

AU - Morgan, Kathryn E.

AU - Yeh, Su Peng

AU - Costello, Caitlin L.

AU - Berdeja, Jesus G.

AU - Davies, Faith E.

AU - Zonder, Jeffrey A.

AU - Lee, Hans C.

AU - Omel, Jim

AU - Spencer, Andrew

AU - Terpos, Evangelos

AU - Hungria, Vania T.M.

AU - Puig, Noemi

AU - Fu, Chengcheng

AU - Ferrari, Renda H.

AU - Ren, Kaili

AU - Stull, Dawn Marie

AU - Chari, Ajai

PY - 2023/3

Y1 - 2023/3

N2 - Background: Infections are a common reason for hospitalization and death in multiple myeloma (MM). Although pneumococcal vaccination (PV) and influenza vaccination (FV) are recommended for MM patients, data on vaccination status and outcomes are limited in MM. Materials and Methods: We utilized data from the global, prospective, observational INSIGHT MM study to analyze FV and PV rates and associated outcomes of patients with MM enrolled 2016-2019. Results: Of the 4307 patients enrolled, 2543 and 2500 had study-entry data on FV and PV status. Overall vaccination rates were low (FV 39.6%, PV 30.2%) and varied by region. On separate multivariable analyses of overall survival (OS) by Cox model, FV in the prior 2 years and PV in the prior 5 years impacted OS (vs. no vaccination; FV: HR, 0.73; 95% CI, 0.60-0.90; P = .003; PV: HR, 0.51; 95% CI, 0.42-0.63; P < .0001) when adjusted for age, region, performance status, disease stage, cytogenetics at diagnosis, MM symptoms, disease status, time since diagnosis, and prior transplant. Proportions of deaths due to infections were lower among vaccinated versus non-vaccinated patients (FV: 9.8% vs. 15.3%, P = .142; PV: 9.9% vs. 18.0%, P = .032). Patients with FV had generally lower health resource utilization (HRU) versus patients without FV; patients with PV had higher or similar HRU versus patients without PV. Conclusion: Vaccination is important in MM and should be encouraged. Vaccination status should be recorded in prospective clinical trials as it may affect survival. This trial was registered at www.clinicaltrials.gov as #NCT02761187.

AB - Background: Infections are a common reason for hospitalization and death in multiple myeloma (MM). Although pneumococcal vaccination (PV) and influenza vaccination (FV) are recommended for MM patients, data on vaccination status and outcomes are limited in MM. Materials and Methods: We utilized data from the global, prospective, observational INSIGHT MM study to analyze FV and PV rates and associated outcomes of patients with MM enrolled 2016-2019. Results: Of the 4307 patients enrolled, 2543 and 2500 had study-entry data on FV and PV status. Overall vaccination rates were low (FV 39.6%, PV 30.2%) and varied by region. On separate multivariable analyses of overall survival (OS) by Cox model, FV in the prior 2 years and PV in the prior 5 years impacted OS (vs. no vaccination; FV: HR, 0.73; 95% CI, 0.60-0.90; P = .003; PV: HR, 0.51; 95% CI, 0.42-0.63; P < .0001) when adjusted for age, region, performance status, disease stage, cytogenetics at diagnosis, MM symptoms, disease status, time since diagnosis, and prior transplant. Proportions of deaths due to infections were lower among vaccinated versus non-vaccinated patients (FV: 9.8% vs. 15.3%, P = .142; PV: 9.9% vs. 18.0%, P = .032). Patients with FV had generally lower health resource utilization (HRU) versus patients without FV; patients with PV had higher or similar HRU versus patients without PV. Conclusion: Vaccination is important in MM and should be encouraged. Vaccination status should be recorded in prospective clinical trials as it may affect survival. This trial was registered at www.clinicaltrials.gov as #NCT02761187.

KW - Infection

KW - Multiple myeloma

KW - Supportive care

KW - Survival

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85146453708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146453708&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2022.12.003

DO - 10.1016/j.clml.2022.12.003

M3 - Article

C2 - 36641358

AN - SCOPUS:85146453708

SN - 2152-2650

VL - 23

SP - e171-e181

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 3

ER -

Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this